A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

Modern Rheumatology, 05/14/2012

Serum Krebs von den Lungen–6 (KL–6) levels may increase during treatment with methotrexate (MTX) or these biological disease–modifying antirheumatic drugs (DMARDs) without significant clinical events.

Print Article Summary Cat 2 CME Report